These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

63 related articles for article (PubMed ID: 6940657)

  • 21. [Comparision of high dose impulsion and low dose density chemotherapeutic regimens with paclitaxel plus cisplatin in advanced NSCLC].
    Hua XM; Ren XW; Liu FL; Liu Y; Zhang CJ; Li ZJ; Xu L; Liu JY; Liu YG
    Zhonghua Zhong Liu Za Zhi; 2004 Oct; 26(10):621-5. PubMed ID: 15634526
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Asparaginase and methotrexate combination chemotherapy in relapsed acute lymphoblastic leukemia in adults.
    Yap BS; McCredie KB; Keating MJ; Bodey GP; Freireich EJ
    Cancer Treat Rep; 1981; 65 Suppl 1():83-7. PubMed ID: 6948610
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Chronotherapy with high dose carboplatin, 5-fluorouracil and leucovorin in advanced colorectal carcinoma].
    Popov I; Jelić S; Radosavljević D; Nikolić-Tomasević A
    Srp Arh Celok Lek; 1998; 126(9-10):355-61. PubMed ID: 9863407
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Rituximab plus cladribine with or without cyclophosphamide in patients with relapsed or refractory chronic lymphocytic leukemia.
    Robak T; Smolewski P; Cebula B; Grzybowska-Izydorczyk O; Błoński JZ
    Eur J Haematol; 2007 Aug; 79(2):107-13. PubMed ID: 17635235
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Long-term follow-up results of hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone (Hyper-CVAD), a dose-intensive regimen, in adult acute lymphocytic leukemia.
    Kantarjian H; Thomas D; O'Brien S; Cortes J; Giles F; Jeha S; Bueso-Ramos CE; Pierce S; Shan J; Koller C; Beran M; Keating M; Freireich EJ
    Cancer; 2004 Dec; 101(12):2788-801. PubMed ID: 15481055
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Combination of high-dose cyclophosphamide, BCNU, and VP-16-213 followed by autologous marrow rescue in the treatment of relapsed leukemia.
    Zander AR; Vellekoop L; Spitzer G; Verma DS; Litam J; McCredie KB; Keating M; Hester JP; Dicke KA
    Cancer Treat Rep; 1981; 65(5-6):377-81. PubMed ID: 7016323
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Phase I--II study of 3-deazauridine in adults with acute leukemia.
    Yap BS; McCredie KB; Keating MJ; Bodey GP; Freireich EJ
    Cancer Treat Rep; 1981; 65(5-6):521-4. PubMed ID: 7237473
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Phase I and II trial of 4'-(9-acridinylamino)methanesulfon-m-anisidide in patients with acute leukemia.
    Arlin ZA; Sklaroff RB; Gee TS; Kempin SJ; Howard J; Clarkson BD; Young CW
    Cancer Res; 1980 Sep; 40(9):3304-6. PubMed ID: 6933002
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Phase I evaluation of beta-2'-deoxythioguanosine in pediatric patients with leukemia.
    Higgins GR; Jamin DC; Shore NA; Momparler R; Hartman G; Siegel SE
    Cancer Treat Rep; 1985 Jun; 69(6):699-701. PubMed ID: 3860294
    [TBL] [Abstract][Full Text] [Related]  

  • 30. High-dose cyclophosphamide in the treatment of refractory lymphomas and solid tumor malignancies.
    Collins C; Mortimer J; Livingston RB
    Cancer; 1989 Jan; 63(2):228-32. PubMed ID: 2910431
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Moderate-dose cyclophosphamide in the treatment of relapsed/refractory T-cell large granular lymphocytic leukemia-associated pure red cell aplasia.
    Peng G; Yang W; Zhang L; Zhou K; Li Y; Li Y; Ye L; Li J; Fan H; Song L; Zhao X; Wu Z; Zhang F; Jing L
    Hematology; 2016 Apr; 21(3):138-43. PubMed ID: 27077768
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Phase-I study of continuous infusion cyclophosphamide for protracted durations: a preliminary report.
    Lokich JJ; Bothe A
    Cancer Drug Deliv; 1984; 1(4):329-32. PubMed ID: 6544128
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Actinomycin D in childhood acute lymphocytic leukemia.
    Green DM; Sallan SE; Krishan A
    Cancer Treat Rep; 1978 May; 62(5):829-31. PubMed ID: 274997
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [KM 2210 therapy for chronic lymphocytic leukemia].
    Mori M; Murai Y; Miwa A; Fukayama M; Ikebuchi K; Nakamura N; Kaise M
    Gan No Rinsho; 1983 Dec; 29(15):1788-90. PubMed ID: 6689433
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [The study of VENP therapy for acute lymphocytic leukemia (author's transl)].
    Yoshikawa H; Maruo K; Ichiniya M; Yamada H; Masaoka T; Takeyama H; Kawashima K; Yamada K
    Rinsho Ketsueki; 1980 Jun; 21(6):778-84. PubMed ID: 6936564
    [No Abstract]   [Full Text] [Related]  

  • 36. The dynamics of morphological and cytoenzymatic changes in peripheral blood lymphocyte lysosomes in patients with chronic lymphocytic leukemia during treatment.
    Grabarczyk M; Sitarska E; Leszko B
    Arch Immunol Ther Exp (Warsz); 1983; 31(4):475-80. PubMed ID: 6670917
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Intensive cyclophosphamide (NSC-26271) therapy for solid tumors.
    Mullins GM; Colvin M
    Cancer Chemother Rep; 1975; 59(2 Pt 1):411-9. PubMed ID: 1097100
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Cutaneous vasculitis due to cyclophosphamide therapy for chronic lymphocytic leukemia.
    Green RM; Schapel GJ; Sage RE
    Aust N Z J Med; 1989 Feb; 19(1):55-7. PubMed ID: 2764806
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A correlation of initial blood counts with survival time in patients with acute lymphocytic leukemia.
    Holyoke EA; Rigby PG
    Nebr State Med J; 1970 Jul; 55(7):410-4. PubMed ID: 4247544
    [No Abstract]   [Full Text] [Related]  

  • 40. Peripheral destruction of platelets in chronic lymphocytic leukemia: recognition, prognosis and therapeutic implications.
    Rubinstein DB; Longo DL
    Am J Med; 1981 Oct; 71(4):729-32. PubMed ID: 7025627
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.